IVA Share Price Performance
€4.38
1.53 (53.68%)
56.1% undervalued intrinsic discount
€9.97
Fair Value
Price €4.38
AnalystConsensusTarget €9.97
AnalystHighTarget €11.40
Fair Value€9.97
Share Pricen/a
Narrative Update • May 19
Inventiva S.A. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 16 Fair Values set on narratives written by author
IVA Community Narratives
AN
Fair Value
·Fair Value €9.97 56.1% undervalued intrinsic discount
Analysts Boost Inventiva Price Target Amid Optimism for MASH Market and Pipeline Progress
0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AN
Fair Value
·Fair Value €11.4 61.6% undervalued intrinsic discount
Global Aging Trends Will Spark Demand For MASH Treatments
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Analysts Boost Inventiva Price Target Amid Optimism for MASH Market and Pipeline Progress
Inventiva is betting big on a single liver disease pill, and upcoming trial results could decide whether it becomes one of the few easy-to-take options for patients. The company is cutting back other work to focus on this shot, but that also raises the stakes if the lead drug disappoints.Read more
AN
€9.97
56.1% undervalued intrinsic discount
Fair Value
Profit Margin
6.59%
Future PE
273.22x
Price in 2029
€12.16
Global Aging Trends Will Spark Demand For MASH Treatments
Key Takeaways Leadership in multimodal metabolic therapies and innovative clinical positioning could drive outsized revenue and expand Inventiva's market reach over time. Decisive restructuring and strategic partnerships enhance margins and acquisition appeal, positioning the company for industry-leading financial performance and transformative growth opportunities.Read more
AN
€11.4
61.6% undervalued intrinsic discount
Fair Value
Profit Margin
35.4%
Future PE
13.54x
Price in 2029
€13.81
Trending Discussion
Recently Updated Narratives
AN
IVA: 2026 MASH Phase 3 Readout Will Underpin Bullish Repricing Outlook
Fair Value: €9.97 56.1% undervalued intrinsic discount
12 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
IVA: Bullish MASH Program Coverage Will Highlight Upcoming Clinical Milestone Catalysts
Fair Value: €11.4 61.6% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Inventiva S.A. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Sep 25, 2026
- -1.70
- 99.67%
- -5,237.95%
- -799.8%
About IVA
- Founded
- 2011
- Employees
- 73
- CEO
- WebsiteView website
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Recent IVA News & Updates
Narrative Update • May 04
